EA201201222A1 - SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) - Google Patents
SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS)Info
- Publication number
- EA201201222A1 EA201201222A1 EA201201222A EA201201222A EA201201222A1 EA 201201222 A1 EA201201222 A1 EA 201201222A1 EA 201201222 A EA201201222 A EA 201201222A EA 201201222 A EA201201222 A EA 201201222A EA 201201222 A1 EA201201222 A1 EA 201201222A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- solid dosage
- action
- possessing
- options
- solid medicine
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к области фармацевтической промышленности и медицине и может быть использовано при создании и применении твердых лекарственных форм для лечения и/или профилактики ожирения. Задачей настоящего изобретения является создание эффективной твердой лекарственной формы с использованием сибутрамина гидрохлорида моногидрата, обладающей анорексигенным действием. Задача решается за счет введения в состав твердой лекарственной формы дополнительных минеральных веществ, а также за счет использования изотопов углеродаС и азотаN. Техническими результатами изобретения являются увеличение лечебного эффекта (снижение веса тела или уменьшение скорости прироста веса тела) при сохранении продолжительности действия без увеличения концентрации сибутрамина гидрохлорида моногидрата при лечении и/или профилактики ожирения; сокращение времени наступления лечебного эффекта.The invention relates to the pharmaceutical industry and medicine and can be used in the creation and use of solid dosage forms for the treatment and / or prevention of obesity. The present invention is the creation of an effective solid dosage form using sibutramine hydrochloride monohydrate with anorexigenic action. The problem is solved by introducing into the solid dosage form additional minerals, as well as through the use of carbon isotopes and nitrogen. The technical results of the invention are to increase the therapeutic effect (decrease in body weight or decrease in the rate of weight gain) while maintaining the duration of action without increasing the concentration of sibutramine hydrochloride monohydrate in the treatment and / or prevention of obesity; reducing the time of onset of therapeutic effect.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201201222A EA020061B1 (en) | 2012-10-02 | 2012-10-02 | Solid dosage form having an anorectic effect (variants) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201201222A EA020061B1 (en) | 2012-10-02 | 2012-10-02 | Solid dosage form having an anorectic effect (variants) |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201201222A1 true EA201201222A1 (en) | 2013-04-30 |
EA020061B1 EA020061B1 (en) | 2014-08-29 |
Family
ID=48183086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201201222A EA020061B1 (en) | 2012-10-02 | 2012-10-02 | Solid dosage form having an anorectic effect (variants) |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA020061B1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8591801A1 (en) * | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | BENZAMID INHIBITORS OF THE P2X7 RECEIVER. |
RU2426443C2 (en) * | 2007-02-23 | 2011-08-20 | Хилл'С Пет Ньютришн, Инк. | Compositions and methods for animal weight control (versions) |
-
2012
- 2012-10-02 EA EA201201222A patent/EA020061B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EA020061B1 (en) | 2014-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016005532A (en) | Methods for using nitric oxide in a plasma state to treat medical conditions and diseases. | |
EA201790195A1 (en) | METHODS OF TREATING CANCER WITH THE USE OF TIGIT INHIBITORS AND ANTI-CANCER AGENTS | |
MX2022013172A (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia. | |
MX2022003072A (en) | Use of pridopidine for treating functional decline. | |
MX2019006900A (en) | Methods of therapeutic monitoring of nitrogen scavenging drugs. | |
EA201490378A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS USING THE COMBINATION OF LACHINIMODA AND INTERFERON-β | |
EA201391286A1 (en) | TREATMENT OF SOLID TUMORS | |
PH12018501443A1 (en) | Methods of administering hepcidin | |
NZ702730A (en) | Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments | |
MX2018010223A (en) | Combination therapy for treatment of ovarian cancer. | |
PH12016501554A1 (en) | Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug | |
EA201490045A1 (en) | DEUTERED 1-PIPERAZINO-3-PHENYLINDANES USED TO TREAT SCHIZOPHRENIA | |
MY186840A (en) | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy | |
NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
MY180772A (en) | Novel therapeutic mirtazapine combinations for use in pain disorders | |
PH12019501358A1 (en) | Methods of administering hepcidin | |
EA201201222A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201209A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201224A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201223A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201225A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201210A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201211A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201207A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
GB201115977D0 (en) | Neurodevelopmental disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |
|
NF4A | Restoration of lapsed right to a eurasian patent |
Designated state(s): RU |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |